Latest Articles
-
Merck Intensifies Efforts To Tap The Biologics Market With New R&D Head
A few days back Merck (NYSE:MRK) inked a deal with Samsung Bioepis (Read Merck Partners With Samsung Bioepis To Tap Billion Dollar Biosimilars Market ), signaling the drug maker’s renewed focus on biologics and biosimilars (generics of biol...
-
Weekly Healthcare Notes: Abbott Labs, Merck, Pfizer & JNJ
The past week has been eventful for the healthcare sector, impacting many healthcare companies under our coverage. Firstly, the news of first ever case of a child being functionally cured of HIV infection surfaced and Abbott Labs ‘ (NYSE:AB...
-
George Zavoico Lists 10 Biotech Stocks Poised to Run
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (3/7/13) For the first time in ages, conditions for biotech investment are just right. The ...
-
10 Best Dividend Paying Drug Manufacturing Stocks
Submitted by Dividend Yield as part of our contributors program . The best dividend paying stocks from the major drug manufacturing industry originally published at “ long-term-investments.blogspot.com “. The healthcare sector is a...
-
Small Companies Are Hubs of Future Profit in Regenerative Medicine: Gil Van Bokkelen
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (2/28/13) Gil Van Bokkelen has been in the stem cell industry for more than a decade. I...
-
Merck Patent Cliff: A Look At The Musculoskeletal Drugs Division
The pharmaceutical industry is staring at a revenue loss of around $300 billion due to patent expirations this decade. After the patent on a drug expires, generic manufacturers can replicate and sell the product at much cheaper prices, generall...
-
Merck Partners With Samsung Bioepis To Tap Billion Dollar Biosimilars Market
Merck (NYSE:MRK) has struck a deal with Samsung Bioepis, a joint venture between electronics giant Samsung and Biogen Idec, to tap a nascent but burgeoning biosimilars market. The move comes after Merck has had a series of unsuccessful stints in ...
-
Weekly Healthcare Notes: Pfizer And Roche Holdings
The past week has been a handful of events for the healthcare sector impacting many healthcare companies under our coverage. Pfizer (NYSE:PFE) announced that its largest selling drug Lyrica exhibited similar efficacy as Levetiracetam, a conventio...
-
Weekly Healthcare Notes: Medtronic & Merck
The past week has been a handful of events for the healthcare sector impacting many healthcare companies under our coverage. Medtronic ‘s (NYSE:MDT) brain stimulation devices have shown impressive efficacy in early-stage Parkinson patients....
-
4 BioPharma Catalyst Trades Offering Good Upside Potential
Submitted by Scott Matusow as part of our contributors program . To begin this week, I list four bio-pharma companies I feel have significant catalyst trade upside potential. What exactly is a catalyst trade you might be asking? According to ...
-
Weekly Healthcare Notes: Roche Holdings Strong Pipeline & Merck’s Lawsuit Sets Precedent
The past week has been a handful of events for the healthcare sector impacting many healthcare companies under our coverage. Roche Holdings (PINK:RHHBY) touched new highs after its investigational oncology drug Obinutuzumab (GA101) met its primar...
-
Eight Biotech Growth Names: Greg Wade
Submitted by The Life Sciences Report as part of our contributors program . This interview was conducted by George S. Mack of The Life Sciences Report (2/7/13) The driving principle behind successful biotech investment for Managing Director a...
-
Singulair Patent Loss Hits Merck’s Earnings But International Growth Helps
Merck (NYSE:MRK) announced its quarterly earnings for Q4 2012 last Friday, where it reported an expected decline in revenues. The drug maker recorded $11.7 billion in sales, down 5% year-over-year. Singulair’s patent expiry was the major f...
-
Dr. Oz Highlights Pterostilbene and C3G on Live TV, ChromaDex to Benefit
Submitted by Mike Anthony as part of our contributors program . Mehmet Cengiz Oz, known simply as TV’s Dr. Oz, together with Harvard’s Dr. Eva Selhub of Mass General Hospital, highlighted the natural ingredients pterostilbene and C3G...
-
Merck Earnings Preview: What We Are Watching
Merck (NYSE:MRK) is set to declare its Q4 2012 results this Friday, and we expect the drug maker to report a decline in revenues and profits. The patent expiration of Singulair will hurt growth in the pharmaceutical segment even as animal and con...
